Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending
Authors:
Open Access
- 22 November 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (11) , e2243449
Abstract
The term cascading effect refers to “a process [that], once started, proceeds stepwise to its full, seemingly inevitable, conclusion.”1 In the context of medical care, it refers to follow-up testing or treatment after an unclear or abnormal finding from prior service.2 Care cascades can occur for various reasons and may include a range of testing and procedures from simple to complex, each involving potential benefits and harms. A survey of practicing US internists indicated that almost all respondents reported experiencing cascading tests or treatments after incidental findings without clinically meaningful beneficial outcomes.3Keywords
This publication has 38 references indexed in Scilit:
- Early Detection of Prostate Cancer: AUA GuidelineJournal of Urology, 2013
- Five-Year Downstream Outcomes Following Prostate-Specific Antigen Screening in Older MenJAMA Internal Medicine, 2013
- Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of PhysiciansAnnals of Internal Medicine, 2013
- Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2012
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI: Journal of the National Cancer Institute, 2012
- What Happens After an Elevated PSA Test: The Experience of 13,591 VeteransJournal of General Internal Medicine, 2010
- Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2008
- Cascade Effects of Medical TechnologyAnnual Review of Public Health, 2002
- PREOPERATIVE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2 AND 22 NG./ML. CORRELATE POORLY WITH POST-RADICAL PROSTATECTOMY CANCER MORPHOLOGY: PROSTATE SPECIFIC ANTIGEN CURE RATES APPEAR CONSTANT BETWEEN 2 AND 9 NG./ML.Journal of Urology, 2002
- The Cascade Effect in the Clinical Care of PatientsNew England Journal of Medicine, 1986